Can you write and expand a paper based on the outline below:

Title: Linear Porokeratosis: Systematic Review

I. Abstract
- Briefly summarize the etiology, prevalence, and clinical significance of Linear Porokeratosis.
- State the purpose of the systematic review.
- Summarize the main treatment options and highlight key findings from the discussion.

II. Introduction
A. Etiology
- Discuss mutations in genes like SLC17A9 and MVK, which cause Linear Porokeratosis (1, 2).
B. Prevalence
- Linear Porokeratosis is a rare and uncommon variant of porokeratosis (3).
C. Clinical Significance
- Describe the clinical manifestations and complications, such as potential risk of malignant transformation (4, 5).

III. Treatment/Management Options
A. Topical Therapies
1. Topical Corticosteroids
- Detail the use of clobetasol propionate and other topical corticosteroids in treating Linear Porokeratosis (6, 7).
2. Topical Immunomodulators
- Describe the usage of tacrolimus and imiquimod and their effectiveness in treating the condition (8, 9).
3. Topical Retinoids
- Explain the role of tretinoin, tazarotene, and other retinoids in the treatment of Linear Porokeratosis (10, 11).
4. Topical 5-fluorouracil
- Discuss the application of topical 5-fluorouracil in the management of the condition (12, 13).
B. Photodynamic Therapy
- Explain the process and outcomes of using photodynamic therapy for the treatment of Linear Porokeratosis (14-17).
C. Laser Therapies
1. Pulsed Dye Laser
- Discuss the use of pulsed dye lasers in effectively treating the condition (18, 19).
2. Fractional CO2 Laser
- Explain fractional CO2 laser therapy as a treatment option for Linear Porokeratosis (20, 21).
D. Surgical Procedures
- Describe surgical procedures, such as excision and Mohs micrographic surgery, as last-resort treatment options (22, 23).
E. Systemic Therapies
- Discuss the potential use of treatments such as retinoids, particularly in severe or widespread cases (24, 25).

IV. Discussion
- Compare the effectiveness of the various treatment options.
- Discuss limitations and drawbacks of available treatments.
- Identify risk factors for malignant transformation.
- Suggest avenues for further research or development of new therapies.

V. Conclusion
- Recap the key points discussed.
- Emphasize the importance of early diagnosis and treatment.
- Discuss the need for future research in the field.

VI. References

Please refer to the sources provided in my previous response and the following additional sources. Note that while I have provided more sources, you may still need to further expand and verify them.

4. Bolognia JL, Schaffer JV, Cerroni L. Dermatology. 4th ed. Elsevier; 2018.
5. Weedon D. Weedon’s Skin Pathology. 3rd ed. Churchill Livingstone; 2010.
6. Balasubramanian S, Mangalampalli VR, Vasudevan B. Linear Porokeratosis: An Uncommon Presentation of a Common Condition. Indian J Dermatol. 2017;62(6):632-634.
7. Rajan V, Khandpur S. Linear Porokeratosis: An Unusual Presentation. Indian J Dermatol. 2021;66(3):287-289.
8. Wollina U. Treatment of Porokeratosis with Topical Imiquimod: A Review. J Clin Aesthet Dermatol. 2012;5(6):32-34.
9. Wollina U, Hansel G. Successful Treatment of Linear Porokeratosis with Topical Imiquimod. Acta Dermatovenerol Croat. 2013;21(3):204-206.
10. Bhatia A, Momtaz-T K, Wick B. Topical Retinoids in the Management of Photodamaged Skin: From Theory to Evidence-based Practical Approach. Indian J Dermatol Venereol Leprol. 2011;77(5):611-619.
11. Cho YS, Shin J, Hur J, et al. A Case of Linear Porokeratosis Successfully Treated with Topical Tazarotene. Ann Dermatol. 2018;30(6):722-725.
12. Foroughi F, Firoozabadi MR, Chalangari R, et al. The Efficacy of 5% Topical Tea Lotion in Localized Porokeratosis. Indian J Dermatol. 2020;65(3):206-209.
13. Borman KE, Amon RB. Use of 5-fluorouracil in Dermatology. Clin Med Res. 2016;2(5):37-41.
14. Borgia F, Giuffrida R, Caradonna E, et al. Topical 5-aminolaevulinic acid-photodynamic therapy vs. CO2 laser for treating localized porokeratosis. J Eur Acad Dermatol Venereol. 2013;27(6):781-784.
15. Cuomo M, Montagna M, Bancia C, et al. Comparison Between Pulsed Dye Laser and Methyl Aminolaevulinate Photodynamic Treatment of Porokeratosis. Dermatol Ther (Heidelb). 2011;1(1):7.
16. Alexandroff AB, Sinclair SA, Schallreuter K. Linear Porokeratosis Treated with 5-aminolaevulinic Acid Photodynamic Therapy. Photodiagnosis Photodyn Ther. 2006;3(2):123-126.
17. Skroza N, Proietti I, Pampena R, et al. Photodynamic Therapy for the Management of Porokeratosis. Laser Ther. 2014;23(3):181-186.
18. Bavinck JN, Neumann HA, Smit NP. Patient with Porokeratosis Treated with Pulsed Dye Laser. Lasers Surg Med. 1998;23(3):170-173.
19. Blake PW, Doyle AN, Marquart JD. Pulsed Dye Laser Treatment for Disseminated Superficial Porokeratosis. Lasers Surg Med. 2016;48(7):688-691.
20. Saxena K, Vijaikumar M, Sehgal VN. Linear Porokeratosis: The Success of CO2 Laser Ablation. Int J Dermatol. 2005;44(3):230-232.
21. Cho MJ, Cho KH. Successful Treatment of Linear Porokeratosis Using a Fractional Carbon Dioxide Laser. Dermatol Surg. 2018;44(7):1017-1019.
22. Motley RJ, Borchers A, Dearden C. A Patient with Widespread Linear Porokeratosis. Br J Dermatol. 1998;138(2):336-337.
23. Tran H, Wright NA, Chen SC. Mohs Micrographic Surgery for Porokeratosis. Dermatol Surg. 2004;30(2 Pt 1):228-232.
24. Ciążyńska M, Narbutt J, Woźniacka A, et al. Systemic Retinoids in the Treatment of Actinic Keratosis: A Systematic Review of the Literature. Dermatol Ther (Heidelb). 2020;10(1):39-52.
25. Potekaev N, de Oliveira Hundley RC, Leelasinjaroen P, et al. Acitretin in Dermatology: A Review. J Dermatolog Treat. 2021;32(2):166-174.

VII. Future Perspectives
A. Emerging Treatment Modalities
- Discuss novel treatments, such as RNA interference, gene therapy, and new pharmacological agents, under investigation for potential future use in the management of Linear Porokeratosis (26, 27).
B. Importance of Further Research
- Emphasize the need for additional studies to better understand the etiology, clinical course, and management of the condition.
- Highlight the importance of novel approaches to reduce the risk of malignant transformation and improve patients’ quality of life.

VIII. Limitations
- Discuss the limitations of the current review, such as the potential for uncovered research gaps.
- Talk about the possible publication bias, variety in study designs, and other factors that may influence the available data.

IX. Declarations
A. Author contributions
- Describe the role of each author in the development and completion of the systematic review.
B. Ethical approval and consent to participate/for publication
- Clarify concerns, if applicable, about ethics and consent.
C. Availability of data and materials
- Discuss the data and materials used in the review as well as their availability.
D. Funding
- Disclose any funding sources received for the systematic review.
E. Competing interests/Conflicts of interest
- Declare any competing interests or conflicts of interest among the authors.

Additional Sources:
26. Sullivan TP, Kanigsberg ND, Miller ML. Porokeratosis: A Report of Two Unusual Cases. J Cutan Med Surg. 2002;6(2):120-123.
27. Furue M, Terao H, Rikihisa W, Urabe K, Kinukawa N, Nose Y. Ultraviolet B-induced mRNA Expression for Transglutaminases and Involucrin in Linear Porokeratosis. J Dermatol. 1994;21(10):721-726.